Ask AI

Search

Updates

Loading...

Table of contents

Alpha-1 antitrypsin deficiency

What's new

Updated 2024 EASL guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency-associated liver disease.

Background

Overview

Definition
AATD is an inherited disorder caused by mutations in the SERPINA1 gene, leading to a deficiency or dysfunction of the α-1 antitrypsin protein.
1
Pathophysiology
The pathophysiology of α-1 antitrypsin deficiency involves a deficiency in the α-1 antitrypsin protein. The imbalance of proteases and antiproteases leads to unopposed neutrophil elastase activity and subsequent tissue damage in the lungs.
2
Epidemiology
The prevalence of α-1 antitrypsin deficiency in Europe is estimated at 20 per 100,000 population.
3
Risk factors
The primary risk factor for α-1 antitrypsin deficiency is a genetic predisposition, as the condition is inherited in an autosomal co-dominant manner. Individuals of Northern European descent are particularly susceptible due to a higher likelihood of carrying the defective gene.
4
Disease course
Clinically, patients with α-1 antitrypsin deficiency often present with symptoms such as dyspnea, chronic cough, and recurrent respiratory infections. In some cases, the disease may also manifest as unexplained bronchiectasis. In rare cases, it can also lead to liver disease, including chronic hepatitis, cirrhosis, and HCC.
5
6
Prognosis and risk of recurrence
The prognosis can vary widely among patients. The disease is generally progressive, with the potential for significant lung damage over time.
6

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of alpha-1 antitrypsin deficiency are prepared by our editorial team based on guidelines from the European Association for the Study of the Liver (EASL 2024), the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2022), the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP 2022), the National Comprehensive Cancer Network ...
Show more

Screening and diagnosis

Clinical presentation
As per ERS 2017 guidelines:
Recognize that lung disease in α-1 antitrypsin deficiency generally presents at a younger age than usual COPD and may be misdiagnosed as asthma.
E
Recognize that patients with α-1 antitrypsin deficiency are more likely to have basal emphysema than patients with usual COPD.
E
Create free account

More topics in this section

  • Screening of family relatives

  • Indications for testing (lung disease)

  • Indications for testing (liver disease)

  • Indications for testing (vasculitis)

  • Indications for testing (panniculitis)

Diagnostic investigations

AAT levels
As per EASL 2024 guidelines:
Measure serum α-1 antitrypsin levels as a triage tool for α-1 antitrypsin deficiency testing. Obtain serum α-1 antitrypsin testing in situations without inflammation.
B
Consider using a cut-off of 50 mg/dL (9.2 mcmol/L) as a triage tool to raise suspicion of severe α-1 antitrypsin deficiency.
C

More topics in this section

  • Protein electrophoresis

  • Genetic testing

  • Pulmonary function testing

  • Chest imaging

  • Liver testing

Medical management

Setting of care: as per ERS 2017 guidelines, manage patients with α-1 antitrypsin deficiency in supervision by reference centers of excellence at a national or regional level.
E

More topics in this section

  • Augmentation therapy

  • UDCA

Nonpharmacologic interventions

Lifestyle modifications: as per EASL 2024 guidelines, provide lifestyle counseling as smoking, obesity, and alcohol consumption have negative effects on the health of patients with α-1 antitrypsin deficiency.
B

Surgical interventions

Lung volume reduction surgery: as per ERS 2017 guidelines, consider performing surgical volume reduction and endobronchial valve placement in selected patients with α-1 antitrypsin deficiency, with a careful appraisal of risks and benefits assessed by a multidisciplinary team experienced in lung volume reduction and α-1 antitrypsin deficiency.
E

More topics in this section

  • Lung transplantation

  • Liver transplantation

  • Liver donation

Follow-up and surveillance

Surveillance for lung disease: as per ERS 2017 guidelines, obtain annual pulmonary function testing including post-bronchodilator FEV1 and gas transfer to monitor for disease progression.
E
Show 3 more

More topics in this section

  • Surveillance for liver disease

  • Surveillance for HCC